Meeting Abstract

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Volume: 5 Number: S-1 August 9, 2022
TR EN

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Abstract

Objectives: Oral squamous cell carcinoma (OSCC) has a high morbidity and mortality rates, but there are no reliable biomarkers to define patients in early phases of disease. In our study (TUBITAK-SBAG-114S497), we aimed to investigate the potential epigenetic biomarker candidate genes observed methylation-dependent expression loss via methylation and expression array methods in OSCC patients. Material and Methods: Methylation and expression profiling in tumor and conjugate-normal tissue samples of 6 OSCC patients were analyzed by “IlluminaHumanMethylation450 chips” and “Illumina iScan”, respectively. Methylation/expression array data were analyzed and interpreted by R(v3.5.1) environment using ChAMP and limma/lumi packages, and then the significant decreased expression changes due to hypermethylation of the candidate gene was detected. The selected candidate gene was validated in tumor and matched-normal tissues and body fluids (serum and saliva) of 20 OSCC patients by QRT-PCR/QMSP methods. Results: According to the array results, it was determined that the expression levels of the candidate gene were decreased due to methylation (DiffScore:13.18826; FoldChange:-1.08345). This candidate gene (unpublished data), which plays an important role in ubiquitin-ligase activity, was found to be methylated in 45% tumor, 40% matched-normal tissue, 10% serum and 30% saliva samples. 50% of the patients observed methylation in the tumor tissue showed the differentially decreased expression levels. Conclusion: It is thought that this candidate gene, whose expression level decreased due to methylation, will be a candidate epigenetic biomarker for the early diagnosis of the subtypes of OSCC. Further validation of this candidate gene will be needed in the larger OSCC cohorts.

Keywords

Supporting Institution

TUBITAK

Project Number

TUBITAK-SBAG-114S497

References

  1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Meeting Abstract

Publication Date

August 9, 2022

Submission Date

July 18, 2022

Acceptance Date

July 18, 2022

Published in Issue

Year 2022 Volume: 5 Number: S-1

APA
Demokan, S., Sen, S., Eryılmaz, O., Comert, S., Ulusan, M., & Dalay, M. N. (2022). NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences, 5(S-1), 45-45. https://doi.org/10.26650/JARHS2021-1142702
AMA
1.Demokan S, Sen S, Eryılmaz O, Comert S, Ulusan M, Dalay MN. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences. 2022;5(S-1):45-45. doi:10.26650/JARHS2021-1142702
Chicago
Demokan, Semra, Sena Sen, Onder Eryılmaz, Sevde Comert, Murat Ulusan, and Mehmet Nejat Dalay. 2022. “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”. Journal of Advanced Research in Health Sciences 5 (S-1): 45-45. https://doi.org/10.26650/JARHS2021-1142702.
EndNote
Demokan S, Sen S, Eryılmaz O, Comert S, Ulusan M, Dalay MN (August 1, 2022) NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences 5 S-1 45–45.
IEEE
[1]S. Demokan, S. Sen, O. Eryılmaz, S. Comert, M. Ulusan, and M. N. Dalay, “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”, Journal of Advanced Research in Health Sciences, vol. 5, no. S-1, pp. 45–45, Aug. 2022, doi: 10.26650/JARHS2021-1142702.
ISNAD
Demokan, Semra - Sen, Sena - Eryılmaz, Onder - Comert, Sevde - Ulusan, Murat - Dalay, Mehmet Nejat. “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”. Journal of Advanced Research in Health Sciences 5/S-1 (August 1, 2022): 45-45. https://doi.org/10.26650/JARHS2021-1142702.
JAMA
1.Demokan S, Sen S, Eryılmaz O, Comert S, Ulusan M, Dalay MN. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences. 2022;5:45–45.
MLA
Demokan, Semra, et al. “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”. Journal of Advanced Research in Health Sciences, vol. 5, no. S-1, Aug. 2022, pp. 45-45, doi:10.26650/JARHS2021-1142702.
Vancouver
1.Semra Demokan, Sena Sen, Onder Eryılmaz, Sevde Comert, Murat Ulusan, Mehmet Nejat Dalay. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences. 2022 Aug. 1;5(S-1):45-. doi:10.26650/JARHS2021-1142702